Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 0.18 + web + cancer  Related to the article below (Last Update: 8/4/2008)

InvestSource, Inc.: Chang-On International Inc. Now Listed in ...
Trading Markets (press release), CA - Aug 1, 2008
The Standard & Poor's 500 index fell 16.88, or 1.31 percent, to 1267.38, while the Nasdaq fell 4.17, or 0.18 percent, to 2325.55. ABOUT INVESTSOURCE, INC. ...OTC:CAON - CPF - PM
IRIS Reports Record Second Quarter Revenues, Profit and EPS, and ...
Trading Markets (press release), CA - Jul 28, 2008
IRIS will submit a new 510(k) seeking clearance of a prognostic claim for identifying post-prostatectomy patients with low-risk of prostate cancer ...IRIS
Source: Google News

Use and Benefits of a Web Site for Pancreatic Cancer -
M Goggins, A Lietman, RE Miller, CJ Yeo, E Jaffee, … - JAMA, 1998 - Am Med Assoc
... Rural vs urban (26/171 vs 20/84) 0.37 (0.18-0.76) .007 ... Thedepartmentofpathologyat
theJohnsHopkinsHospital maintains the Pancreatic Cancer Web site. ...

Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk -
H Cui, M Cruz-Correa, FM Giardiello, DF Hutcheon, … - Science, 2003 - sciencemag.org
... a browser that does not support current Web standards ... of colorectal neoplasia
(adenomatous polyps or cancer) were 4.72 ... 17 (85.0), 3 (15.0), 1.00, 1.04, 0.18 to ...

Computer Support for Elderly Women With Breast Cancer -
DH Gustafson, F McTavish, R Hawkins, S Pingree, N … - JAMA, 1998 - Am Med Assoc
... 33%); and ?Mastectomy: A Treatment for Breast Cancer? (30 ... bulk of information on
the World Wide Web, ie, the ... urban (26/171 vs 20/84) 0.37 (0.18-0.76) .007 ...

Dietary lignan intakes and risk of pre- and postmenopausal breast cancer -
SE McCann, P Muti, D Vito, SB Edge, M Trevisan, JL … - International Journal of Cancer, 2004 - doi.wiley.com
... R 2 change 0.50), fruit cocktail (0.18), coffee (0.17 ... CONFIDENCE INTERVALS FOR RISK
OF BREAST CANCER ASSOCIATED WITH DIETARY LIGNAN INTAKE: WEB STUDY (1996 ...

Cancer Statistics, 2007 -
A Jemal, R Siegel, E Ward, T Murray, J Xu, MJ Thun - CA: A Cancer Journal for Clinicians, 2007 - Am Cancer Soc
... Michael Cancer Statistics, 2007 This information is current as of January 30, 2007
http://caonline.amcancersoc.org/cgi/content/full/57/1/43 the World Wide Web ...

Internet Breast Health Information Use and Coping among Women with Breast Cancer -
J Fogel - CyberPsychology & Behavior, 2004 - liebertonline.com
... Humor 3.74 (1.85) 3.74 (2.12) 0.00 0.32 0.18 ... for consumers on the world wide web:
a systematic review ... The Internet for medical information about cancer: help or ...

Applicability and Quality of Information for Answering Clinical Questions on the Web -
WR Hersh, PN Gorman, LS Sacherek - JAMA, 1998 - Am Med Assoc
... 33%); and ?Mastectomy: A Treatment for Breast Cancer? (30 ... bulk of information on
the World Wide Web, ie, the ... urban (26/171 vs 20/84) 0.37 (0.18-0.76) .007 ...

Gastrointestinal cancer web sites: how do they address patients? concerns? -
C Weissenberger, D M?ller, J Beranek-Chiu, M … - International Journal of Colorectal Disease, 2006 - Springer
... Tumor entities Anal cancer 20 69, 2 0.18 Intestinal cancer 40 77 ... 87, 7 Esophageal
cancer 25 71, 7 Gullet cancer 3 93 ... 12 112, 9 Owners of the web sites Commercial ...

… throughout life and risk of breast cancer: the Western New York Exposures and Breast Cancer (WEB) … -
J Nie, J Beyea, MR Bonner, D Han, JE Vena, P … - Cancer Causes and Control, 2007 - Springer
... to traffic emissions throughout life and risk of breast cancer by smoking status,
WEB Study, 1996 ... 3: 16 48 1.42 (0.40?5.11) 23 46 0.60 (0.18?2.00) ...

Cancer screening guidelines -
R Zoorob, R Anderson, C Cefalu, M Sidani - Am Fam Physician, 2001 - aafp.org
... the risk of cervical cancer mortality by only 0.18 percent at age 65 ... Retrieved September
21, 2000, from the World Wide Web: http://www.cancer.org/statistics ...
-

Source: Google Scholar
 
 

What Cures Your Aches Might Prevent Cancer

Article Date: 02 Dec 2006 - 17:00pm (PST)
Mayo Clinic Cancer Center has begun three clinical studies looking at the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent cancer -- colon, esophageal or lung. These studies are part of the ongoing Cancer Center chemoprevention program, using medications to prevent cancer, especially for people with increased cancer risk.

"While searching for the cure is important, even more so is finding effective ways to prevent cancer," says Paul Limburg, M.D., M.P.H., Mayo Clinic gastroenterologist and lead researcher on the colon cancer prevention study. "We have observed that some of the same biological processes that cause inflammation may also be involved in developing cancer, so the next step was to see if drugs that prevent inflammation also serve to lessen the risk of cancer."

The colon cancer study is looking at the NSAID sulindac (Clinoril), and its ability to inhibit inflammation and subsequent transformation of damaged cells into cancer cells. Sulindac's preventive effect will be measured against that of two other potential prevention agents: atorvastatin (Lipitor), a cholesterol-lowering drug with some reported cancer prevention aspects (Cancer Research, April and July 2006); and Raftilose-Synergy1, a food supplement derived from chicory, also with some supporting research conducted overseas (The British Journal of Nutrition, April 2005).

Article continues below and (thank you)
 
Dr. Limburg's team will treat patients at increased risk for developing colon cancer, specifically individuals age 40 or older who have advanced colorectal adenoma (precancerous tissues) or a history of colon cancer with treatment completed more than one year prior to entering the study. Tissues and blood samples will be tested pre-treatment and post-treatment to determine the preventive effects of the different medications.

Other gastroenterologists at Mayo are looking at NSAID use for patients with Barrett's esophagus. "There is evidence to support the idea that taking an NSAID will slow or reverse precancerous conditions such as Barrett's esophagus," Dr. Limburg says. "Prognosis for esophageal cancer patients is poor. We are continually looking for ways to prevent this and other cancers from ever starting, and NSAIDs provide a promising avenue for our research."

Individuals eligible for the esophageal cancer prevention study will receive esomeprazole (Nexium), an acid reflux medication, and aspirin, an NSAID. Mayo's doctors hope that using the acid reflux medication will diminish inflammation caused by acid reflux and that the aspirin will continue the healing and prevention process. Tissue in the esophagus will be tested before and after treatment to determine the benefits, if any.

The lung cancer prevention study is directed at current or former heavy smokers, age 45 or older, who are in generally good health. Those in cancer remission may be eligible to participate, if their last treatment was at least one year ago. This study is also using sulindac, which will be administered to patients with abnormal, precancerous tissues in their lungs. Pre-drug and post-drug treatment tests will determine effectiveness by reviewing the degree of abnormality of the patients' lung tissues after treatment.

"We have high hopes for all of these studies," says Dr. Limburg. "Previous work has shown that these are promising prevention avenues to pursue, and, if positive, the findings could result in substantial benefit to patients and society from a decreased cancer burden."

Mayo Clinic Cancer Center is offering the clinical studies under the auspices of membership in the Cancer Prevention Network (CPN). Dr. Limburg is the primary investigator for CPN, which is a consortium of 35 community clinics, hospitals and medical centers throughout the United States and Canada. Mayo is the lead organization and research data center for the Cancer Prevention Network, which focuses much of its research efforts on the most wide-spread and deadliest cancers.

###

More information on cancer-related clinical studies ongoing at Mayo Clinic can be found at http://clinicaltrials.mayo.edu/.

These research studies are assisted in part by Astra-Zeneca, Bayer, Boston Scientific, Fujinon, Olympus and Orafti, Inc.

Contact: Elizabeth Zimmermann
Mayo Clinic
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page